Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose of Vandetanib with a current standard first-line
chemotherapy regimen, capecitabine and oxaliplatin without and then with bevacizumab for the
first line treatment of metastatic colorectal cancer (CRC) and to define the dose limiting
toxicities associated with the combination.